跳至主要内容
临床试验/NCT04673071
NCT04673071Unknown不适用

Effectiveness and Safety of Thread Embedding Acupuncture for Drug Resistant Epilepsy: a Randomized Clinical Trial

University of Medicine and Pharmacy at Ho Chi Minh City1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年11月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
60
试验地点
1
主要终点
Seizure freedom

研究概览

简要总结

Epilepsy is one of the most common neurological diseases all over the world. Currently, about 70 million people have epilepsy worldwide. In particular, more than 30% of epilepsy patients still have seizures even though they are treated with appropriate anti-epileptic drugs (AEDs). This number has remained unchanged even after more than 20 years with many new anti-epileptic drugs being introduced. According to International League Against Epilepsy (ILAE), drug-resistant epilepsy is defined when a patient does not achieve seizure-free the seizure with two optimal antiepileptic drugs. This clinical trial is designed to evaluate the effectiveness and safety of thread-embedding acupuncture (TEA) as palliative treatment of drug resistant epilepsy.

详细描述

The objectives of this clinical trial are twofold: the effectiveness of TEA is assessed by comparing the changes in the seizure control and quality of life at 5 months between 2 groups: the TEA + baseline AEDs group and the sham-TEA (STEA) + baseline AEDs group. Adverse events (AEs) that occur during the study will be investigated to evaluate the safety of TEA.

This study is investigated by the following hypotheses:

  • TEA can increase the probability of becoming seizure free.
  • TEA can reduce the frequency and duration of seizures.
  • TEA can improve quality of life.
  • TEA is associated with adverse effects.

This clinical trial will be performed as a 2-arm parallel design, randomized, controlled, assessor-blinded, clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •People with drug resistant epilepsy
  • •Volunteers who agree to participate and sign the Informed Consent Form, following a detailed explanation of clinical trials

排除标准

  • •Under epilepsy surgery
  • •Inappropriate condition for thread-embedding acupuncture due to skin disease (the skin of the acupuncture point is swollen, hot, and red) or hemostatic disorder (PT INR (international normalized ratio )> 2.0 or taking anticoagulant)
  • •Pregnant women or other inappropriate condition for thread-embedding acupuncture
  • •Other diseases that could affect or interfere with therapeutic outcomes, including body exhaustion, severe gastrointestinal disease, cardiovascular disease, hypertension, diabetes, renal disease, liver disease or thyroid disorder
  • •TEA within 6 months previous
  • •Psychiatric disorder currently undergoing treatment such as depression or schizophrenia
  • •Heavy drinking (more than 3 cups per day)

研究组 & 干预措施

Thread Embedding Acupuncture (TEA)

Active Comparator

TEA once a month for 4 months + AEDs

干预措施: Thread Embedding Acupuncture (TEA) (Other)

Sham-TEA (STEA)

Sham Comparator

STEA once a month for 4 months + AEDs

干预措施: Sham-TEA (STEA) (Other)

结局指标

主要结局

Seizure freedom

时间窗: 1 Month

Percentage of seizure reduction in seizure frequency compared to baseline seizure frequency. Seizure frequency is recorded by the participants using seizure diary.

Quality of life (QOL)

时间窗: 5 months

Quality of life was recorded by QOLIE-31 (Quality of Life in Epilepsy) questionnaire The Quality of Life in Epilepsy Inventory (QOLIE-31) contains seven multi-item scales that tap the following health concepts: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall quality of life. The scoring procedure for the QOLIE-31 first converts the raw coded numeric values of items to 0-100 point scores, with higher converted scores always reflecting better quality of life.

次要结局

  • Epileptiform discharges(5 months)
  • Seizure Severity(3 months)

研究者

发起方
University of Medicine and Pharmacy at Ho Chi Minh City
申办方类型
Other
责任方
Principal Investigator
主要研究者

Minh-An Thuy Le

Lecturer, Principle Investigator

University of Medicine and Pharmacy at Ho Chi Minh City

研究点 (1)

Loading locations...

相似试验